Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer.
Mack KN, Bauer D, Carter LM, Carrasco SE, Atmane MI, Viray TD, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS.
Mack KN, et al.
Nucl Med Biol. 2024 Nov 22;140-141:108976. doi: 10.1016/j.nucmedbio.2024.108976. Online ahead of print.
Nucl Med Biol. 2024.
PMID: 39615062